Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auriga Laboratories has reported the signing of a manufacturing and supply agreement with Mikart, pursuant to which Auriga will have the rights to market and sell a new product indicated for the relief of mild to moderately severe pain, in the US.
Subscribe to our email newsletter
The new pain product combines the effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen, in a unique strength previously not available. The product is expected to launch during the Q2 2008, and will be promoted to primary care practitioners and dentists.
Philip Pesin, CEO of Auriga, said: “This Agreement solidifies Auriga’s commitment to enhance our product portfolio with products approved using the ANDA and 505(b)(2) NDA regulatory pathways.”